Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study (Q34515400)

2 August 2017

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study (English)

1 reference

2 August 2017

0 references

7

H Hartung

1 reference

2 August 2017

Per Soelberg Sørensen

9

object named as

P S Sørensen

1 reference

2 August 2017

G Comi

1

1 reference

2 August 2017

M Filippi

2

1 reference

2 August 2017

F Barkhof

3

1 reference

2 August 2017

L Durelli

4

1 reference

2 August 2017

G Edan

5

1 reference

2 August 2017

O Fernández

6

1 reference

2 August 2017

P Seeldrayers

8

1 reference

2 August 2017

M Rovaris

10

1 reference

2 August 2017

V Martinelli

11

1 reference

2 August 2017

O R Hommes

12

1 reference

2 August 2017

Early Treatment of Multiple Sclerosis Study Group

13

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

2 August 2017

1 reference

2 August 2017

357

1 reference

2 August 2017

1576-1582

1 reference

2 August 2017

9268

1 reference

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Axonal damage in acute multiple sclerosis lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Axonal transection in the lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Detection of ventricular enlargement in patients at the earliest clinical stage of MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

A neurologic rating scale (NRS) for use in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Axonal pathology in multiple sclerosis: relationship to neurologic disability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Why treat early multiple sclerosis patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2904725-5

7 January 2021

10.1016/S0140-6736(00)04725-5

Identifiers

DOI

1 reference

2 August 2017

1 reference